Liposomal tricurin, a synergistic combination of curcumin, epicatechin gallate and resveratrol, repolarizes tumor-associated microglia/macrophages, and eliminates glioblastoma (GBM) and GBM Stem Cells

Molecules

Volumn 23, Issue 1, 2018, Pages

  Mukherjee, Sumit ^a   Baidoo, Juliet N E ^a   Sampat, Samay ^c   Mancuso, Andrew ^a,b   David, Lovena ^b   Cohen, Leah S ^b   Zhou, Shuiqin ^b   Banerjee, Probal ^b  

^a CITY UNIVERSITY OF NEW YORK   (United States)

^b CITY UNIVERSITY OF NEW YORK   (United States)

^c NEW YORK UNIVERSITY   (United States)

Author keywords

Curcumin; Epicatechin gallate; GBM stem cells; Glioblastoma multiforme (GBM); Liposomes; NK cells; Resveratrol; TriCurin; Tumor associated microglia macrophages (TAM)

Indexed keywords

CATECHIN; CURCUMIN; EPICATECHIN GALLATE; LIPOSOME; PROTEIN P53; RESVERATROL; STILBENE DERIVATIVE; TUMOR MARKER;

ANALOGS AND DERIVATIVES; ANIMAL; CANCER STEM CELL; CHEMISTRY; DISEASE MODEL; DRUG COMBINATION; DRUG EFFECT; DRUG POTENTIATION; DRUG SCREENING; GLIOBLASTOMA; HUMAN; IMMUNOLOGY; IMMUNOPHENOTYPING; MACROPHAGE; METABOLISM; MICROGLIA; MOUSE; NATURAL KILLER CELL; PATHOLOGY; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL LINE;

ANIMALS; BIOMARKERS, TUMOR; CATECHIN; CELL LINE, TUMOR; CURCUMIN; DISEASE MODELS, ANIMAL; DRUG COMBINATIONS; DRUG SYNERGISM; GLIOBLASTOMA; HUMANS; IMMUNOPHENOTYPING; KILLER CELLS, NATURAL; LIPOSOMES; LYMPHOCYTES, TUMOR-INFILTRATING; MACROPHAGES; MICE; MICROGLIA; NEOPLASTIC STEM CELLS; STILBENES; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85040989853     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules23010201     Document Type: Article

References (66)

1. Mahaley, M.S.; Mettlin, C.; Natarajan, N.; Laws, E.R.; Peace, B.B. Analysis of patterns of care of brain tumor patients in the united states: A study of the brain tumor section of the AANS and the CNS and the commission on cancer of the ACS. Clin. Neurosurg. 1990, 36, 347–352. [PubMed]
2. Bleeker, F.E.; Molenaar, R.J.; Leenstra, S. Recent advances in the molecular understanding of glioblastoma. J. Neuro-Oncol. 2012, 108, 11–27. [CrossRef] [PubMed]
3. Young, R.M.; Jamshidi, A.; Davis, G.; Sherman, J.H. Current trends in the surgical management and treatment of adult glioblastoma. Ann. Transl. Med. 2015, 3, 121. [CrossRef] [PubMed]
4. Stupp, R.; Mason, W.P.; van den Bent, M.J.; Weller, M.; Fisher, B.; Taphoorn, M.J.; Belanger, K.; Brandes, A.A.; Marosi, C.; Bogdahn, U.; et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 2005, 352, 987–996. [CrossRef] [PubMed]
5. Wen, P.Y.; Kesari, S. Malignant gliomas in adults. N. Engl. J. Med. 2008, 359, 492–507. [CrossRef] [PubMed]
6. Wick, W.; Platten, M.; Weller, M. New (alternative) temozolomide regimens for the treatment of glioma. Neuro Oncol. 2009, 11, 69–79. [CrossRef] [PubMed]
7. Neyns, B.; Chaskis, C.; Joosens, E.; Menten, J.; D’Hondt, L.; Branle, F.; Sadones, J.; Michotte, A. A multicenter cohort study of dose-dense temozolomide (21 of 28 days) for the treatment of recurrent anaplastic astrocytoma or oligoastrocytoma. Cancer Investig. 2008, 26, 269–277. [CrossRef] [PubMed]
8. Takano, T.; Lin, J.H.; Arcuino, G.; Gao, Q.; Yang, J.; Nedergaard, M. Glutamate release promotes growth of malignant gliomas. Nat. Med. 2001, 7, 1010–1015. [CrossRef] [PubMed]
9. Bao, S.; Wu, Q.; McLendon, R.E.; Hao, Y.; Shi, Q.; Hjelmeland, A.B.; Dewhirst, M.W.; Bigner, D.D.; Rich, J.N. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006, 444, 756–760. [CrossRef] [PubMed]
10. Su, Y.B.; Sohn, S.; Krown, S.E.; Livington, P.O.; Wolchek, J.D.; Quinn, C.; Williams, L.; Foster, T.; Sepkowitz, K.A.; Chapman, P.B. Selective CD4 lymphopenia in melanoma patients treated with temozolomide: A toxicity with therapeutic implications. J. Clin. Oncol. 2004, 22, 610–616. [CrossRef] [PubMed]
11. Happold, C.; Roth, P.; Wick, W.; Schmidt, N.; Florea, A.M.; Silginer, M.; Reifenberger, G.; Weller, M. Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells. J. Neurochem. 2012, 122, 444–455. [CrossRef] [PubMed]
12. Huang, B.; Zhang, H.; Gu, L.; Ye, B.; Jian, Z.; Stary, C.; Xiong, X. Advances in immunotherapy for glioblastoma multiforme. J. Immunol. Res. 2017, 2017, 11. [CrossRef] [PubMed]
13. Lu, Y.; Miao, L.; Wang, Y.; Xu, Z.; Zhao, Y.; Shen, Y.; Xiang, G.; Huang, L. Curcumin micelles remodel tumor microenvironment and enhance vaccine activity in an advanced melanoma model. Mol. Ther. J. Am. Soc. Gene Ther. 2016, 24, 364–374. [CrossRef] [PubMed]
14. Mukherjee, S.; Baidoo, J.; Fried, A.; Atwi, D.; Dolai, S.; Boockvar, J.; Symons, M.; Ruggieri, R.; Raja, K.; Banerjee, P. Curcumin changes the polarity of tumor-associated microglia and eliminates glioblastoma. Int. J. Cancer 2016, 139, 2838–2849. [CrossRef] [PubMed]
15. Shiri, S.; Alizadeh, A.M.; Baradaran, B.; Farhanghi, B.; Shanehbandi, D.; Khodayari, S.; Khodayari, H.; Tavassoli, A. Dendrosomal curcumin suppresses metastatic breast cancer in mice by changing m1/m2 macrophage balance in the tumor microenvironment. Asian Pac. J. Cancer Prev. 2015, 16, 3917–3922. [CrossRef] [PubMed]
16. Smith, A.; Andreansky, S. Antitumor immunity and dietary compounds. Med. Sci. 2014, 2, 1–22. [CrossRef]
17. Ye, X.-Z.; Xu, S.-L.; Xin, Y.-H.; Yu, S.-C.; Ping, Y.-F.; Chen, L.; Xiao, H.-L.; Wang, B.; Yi, L.; Wang, Q.-L.; et al. Tumor-associated microglia/macrophages enhance the invasion of glioma stem-like cells via TGF-β1 signaling pathway. J. Immunol. 2012, 189, 444–453. [CrossRef] [PubMed]
18. Schapira, A.H.V. Neurology and Clinical Neuroscience E-Book; Elsevier Health Sciences: Amsterdam, The Netherlands, 2006.
19. Bhattacharyya, S.; Mandal, D.; Saha, B.; Sen, G.S.; Das, T.; Sa, G. Curcumin prevents tumor-induced T cell apoptosis through stat-5a-mediated bcl-2 induction. J. Biol. Chem. 2007, 282, 15954–15964. [CrossRef] [PubMed]
20. Debata, P.R.; Castellanos, M.R.; Fata, J.E.; Baggett, S.; Rajupet, S.; Szerszen, A.; Begum, S.; Mata, A.; Murty, V.V.; Opitz, L.M.; et al. A novel curcumin-based vaginal cream vacurin selectively eliminates apposed himan cervical cancer cells. Gynecol. Oncol. 2013, 129, 145–153. [CrossRef] [PubMed]
21. Langone, P.; Debata, P.R.; Dolai, S.; Curcio, G.M.; Inigo, J.D.; Raja, K.; Banerjee, P. Coupling to a cancer cell-specific antibody potentiates tumoricidal properties of curcumin. Int. J. Cancer 2012, 131, E569–E578. [CrossRef] [PubMed]
22. Langone, P.; Debata, P.R.; Inigo, J.D.R.; Dolai, S.; Mukherjee, S.; Halat, P.; Mastroianni, K.; Curcio, G.M.; Castellanos, M.R.; Raja, K.; et al. Coupling to a glioblastoma-directed antibody potentiates anti-tumor activity of curcumin. Int. J. Cancer 2014, 135, 710–719. [CrossRef] [PubMed]
23. Li, Y.; Zhang, T. Targeting cancer stem cells by curcumin and clinical applications. Cancer Lett. 2014, 346, 197–205. [CrossRef] [PubMed]
24. Lim, K.J.; Bisht, S.; Bar, E.E.; Maitra, A.; Eberhart, C.G. A polymeric nanoparticle formulation of curcumin inhibits growth, clonogenicity and stem-like fraction in malignant brain tumors. Cancer Biol. Ther. 2011, 11, 464–473. [CrossRef] [PubMed]
25. Maher, D.M.; Bell, M.C.; O’Donnell, E.A.; Gupta, B.K.; Jaggi, M.; Chauhan, S.C. Curcumin suppresses human papillomavirus oncoproteins, restores p53, Rb, and PTPN13 proteins and inhibits benzo[a]pyrene-induced upregulation of HPV E7. Mol. Carcinog. 2011, 50, 47–57. [CrossRef] [PubMed]
26. Mukherjee, S.; Debata, P.R.; Hussaini, R.; Chatterjee, K.; Baidoo, J.N.E.; Sampat, S.; Szerszen, A.; Navarra, J.P.; Fata, J.; Severinova, E.; et al. Unique synergistic formulation of curcumin, epicatechin gallate and resveratrol, tricurin, suppresses HPV E6, eliminates HPV+ cancer cells, and inhibits tumor progression. Oncotarget 2017, 8, 60904–60916. [CrossRef] [PubMed]
27. Piao, L.; Mukherjee, S.; Chang, Q.; Xie, X.; Li, H.; Castellanos, M.R.; Banerjee, P.; Iqbal, H.; Ivancic, R.; Wang, X.; et al. Tricurin, a novel formulation of curcumin, epicatechin gallate, and resveratrol, inhibits the tumorigenicity of human papillomavirus-positive head and neck squamous cell carcinoma. Oncotarget 2017, 8, 60025–60035. [CrossRef] [PubMed]
28. Purkayastha, S.; Berliner, A.; Fernando, S.S.; Ranasinghe, B.; Ray, I.; Tariq, H.; Banerjee, P. Curcumin blocks brain tumor formation. Brain Res. 2009, 1266C, 130–138. [CrossRef] [PubMed]
29. Yin, H.; Zhou, Y.; Wen, C.; Zhou, C.; Zhang, W.; Hu, X.; Wang, L.; You, C.; Shao, J. Curcumin sensitizes glioblastoma to temozolomide by simultaneously generating ROS and disrupting AKT/mTOR signaling. Oncol. Rep. 2014, 32, 1610–1616. [CrossRef] [PubMed]
30. Anand, P.; Kunnumakkara, A.B.; Newman, R.A.; Aggarwal, B.B. Bioavailability of curcumin: Problems and promises. Mol. Pharm. 2007, 4, 807–818. [CrossRef] [PubMed]
31. Mirzaei, H.; Shakeri, A.; Rashidi, B.; Jalili, A.; Banikazemi, Z.; Sahebkar, A. Phytosomal curcumin: A review of pharmacokinetic, experimental and clinical studies. Biomed. Pharmacother. 2017, 85, 102–112. [CrossRef] [PubMed]
32. Debata, P.R.; Curcio, G.M.; Mukherjee, S.; Banerjee, P. Causal factors for brain tumor and targeted strategies. In Universe of Scales: From Nanotechnology to Cosmology; Laughoff, S., Freund, F., Eds.; Springer: Cham, Switzerland, 2014; Volume 150, pp. 191–204.
33. Li, L.; Braiteh, F.S.; Kurzrock, R. Liposome-encapsulated curcumin: In vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis. Cancer 2005, 104, 1322–1331. [CrossRef] [PubMed]
34. Matloob, A.H.; Mourtas, S.; Klepetsanis, P.; Antimisiaris, S.G. Increasing the stability of curcumin in serum with liposomes or hybrid drug-in-cyclodextrin-in-liposome systems: A comparative study. Int. J. Pharm. 2014, 476, 108–115. [CrossRef] [PubMed]
35. Ranjan, A.P.; Mukerjee, A.; Helson, L.; Gupta, R.; Vishwanatha, J.K. Efficacy of liposomal curcumin in a human pancreatic tumor xenograft model: Inhibition of tumor growth and angiogenesis. Anticancer Res. 2013, 33, 3603–3609. [PubMed]
36. Marczylo, T.H.; Verschoyle, R.D.; Cooke, D.N.; Morazzoni, P.; Steward, W.P.; Gescher, A.J. Comparison of systemic availability of curcumin with that of curcumin formulated with phosphatidylcholine. Cancer Chemother. Pharmacol. 2007, 60, 171–177. [CrossRef] [PubMed]
37. Castriconi, R.; Daga, A.; Dondero, A.; Zona, G.; Poliani, P.L.; Melotti, A.; Griffero, F.; Marubbi, D.; Spaziante, R.; Bellora, F.; et al. NK cells recognize and kill human glioblastoma cells with stem cell-like properties. J. Immunol. 2009, 182, 3530–3539. [CrossRef] [PubMed]
38. Wu, A.; Wei, J.; Kong, L.Y.; Wang, Y.; Priebe, W.; Qiao, W.; Sawaya, R.; Heimberger, A.B. Glioma cancer stem cells induce immunosuppressive macrophages/microglia. Neuro Oncol. 2010, 12, 1113–1125. [CrossRef] [PubMed]
39. Etheridge, M.L.; Campbell, S.A.; Erdman, A.G.; Haynes, C.L.; Wolf, S.M.; McCullough, J. The big picture on nanomedicine: The state of investigational and approved nanomedicine products. Nanomed. Nanotechnol. Biol. Med. 2013, 9, 1–14. [CrossRef] [PubMed]
40. Shao, J.; Fujiwara, T.; Kadowaki, Y.; Fukazawa, T.; Waku, T.; Itoshima, T.; Yamatsuji, T.; Nishizaki, M.; Roth, J.A.; Tanaka, N. Overexpression of the wild-type p53 gene inhibits NF-kappaB activity and synergizes with aspirin to induce apoptosis in human colon cancer cells. Oncogene 2000, 19, 726–736. [CrossRef] [PubMed]
41. Sen, G.S.; Mohanty, S.; Hossain, D.; Md, S.; Bhattacharyya, S.; Banerjee, S.; Chakraborty, J.; Saha, S.; Ray, P.; Bhattacharjee, P.; et al. Curcumin enhances the efficacy of chemotherapy by tailoring p65NFkB-p300 cross-talk in favor of p53–p300 in breast cancer. J. Biol. Chem. 2011, 286, 42232–42247. [CrossRef] [PubMed]
42. Shankar, S.; Srivastava, R.K. Involvement of Bcl-2 family members, phosphatidylinositol 3’-kinase/AKT and mitochondrial p53 in curcumin (diferulolylmethane)-induced apoptosis in prostate cancer. Int. J. Oncol. 2007, 30, 905–918. [CrossRef] [PubMed]
43. Liu, G.; Yuan, X.; Zeng, Z.; Tunici, P.; Ng, H.; Abdulkadir, I.R.; Lu, L.; Irvin, D.; Black, K.L.; Yu, J.S. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol. Cancer 2006, 5, 67. [CrossRef] [PubMed]
44. Bassiouny, A.R.; Zaky, A. Synergistic effect of curcumin on temozolomide inhibition of cancer stem cell-like properties and reduced chemoresistance of glioblastoma C6. In Proceedings of the International Conference on Regenerative & Functional Medicine, Hilton San Antonio Airport, TX, USA, 12–14 November 2012; OMICS Group: Hilton San Antonio Airport, TX, USA, 2012; Volume 2.
45. Cicalese, A.; Bonizzi, G.; Pasi, C.E.; Faretta, M.; Ronzoni, S.; Giulini, B.; Brisken, C.; Minucci, S.; Di Fiore, P.P.; Pelicci, P.G. The tumor suppressor p53 regulates polarity of self-renewing divisions in mammary stem cells. Cell 2009, 138, 1083–1095. [CrossRef] [PubMed]
46. Luo, F.; Song, X.; Zhang, Y.; Chu, Y. Low-dose curcumin leads to the inhibition of tumor growth via enhancing CTL-mediated antitumor immunity. Int. Immunopharmacol. 2011, 11, 1234–1240. [CrossRef] [PubMed]
47. Sarkar, S.; Doring, A.; Zemp, F.J.; Silva, C.; Lun, X.; Wang, X.; Kelly, J.; Hader, W.; Hamilton, M.; Mercier, P.; et al. Therapeutic activation of macrophages and microglia to suppress brain tumor-initiating cells. Nat. Neurosci. 2014, 17, 46–55. [CrossRef] [PubMed]
48. Brantley, E.C.; Guo, L.; Zhang, C.; Lin, Q.; Yokoi, K.; Langley, R.R.; Kruzel, E.; Maya, M.; Kim, S.W.; Kim, S.-J.; et al. Nitric oxide-mediated tumoricidal activity of murine microglial cells. Transl. Oncol. 2010, 3, 380–388. [CrossRef] [PubMed]
49. Oh, T.; Fakurnejad, S.; Sayegh, E.T.; Clark, A.J.; Ivan, M.E.; Sun, M.Z.; Safaee, M.; Bloch, O.; James, C.D.; Parsa, A.T. Immunocompetent murine models for the study of glioblastoma immunotherapy. J. Transl. Med. 2014, 12, 107. [CrossRef] [PubMed]
50. Farag, S.S.; Caligiuri, M.A. Human natural killer cell development and biology. Blood Rev. 2006, 20, 123–137. [CrossRef] [PubMed]
51. Hagemann, T.; Lawrence, T.; McNeish, I.; Charles, K.A.; Kulbe, H.; Thompson, R.G.; Robinson, S.C.; Balkwill, F.R. “Re-educating” tumor-associated macrophages by targeting NF-κB. J. Exp. Med. 2008, 205, 1261–1268. [CrossRef] [PubMed]
52. Leon, L.; Jeannin, J.F.; Bettaieb, A. Post-translational modifications induced by nitric oxide (no): Implication in cancer cells apoptosis. Nitric Oxide Biol. Chem. 2008, 19, 77–83. [CrossRef] [PubMed]
53. Rahat, M.A.; Hemmerlein, B. Macrophage-tumor cell interactions regulate the function of nitric oxide. Front. Physiol. 2013, 4, 144. [CrossRef] [PubMed]
54. Thiery, J.; Safta, T.B.; Ziani, L.; Chouaib, S. Mechanisms of cytotoxic lymphocyte-mediated apoptosis and relationship with the tumor suppressor p53. Crit. Rev. Immunol. 2015, 35, 433–449. [CrossRef] [PubMed]
55. Gertsch, J.; Guttinger, M.; Heilmann, J.; Sticher, O. Curcumin differentially modulates mRNA profiles in Jurkat T and human peripheral blood mononuclear cells. Bioorg. Med. Chem. 2003, 11, 1057–1063. [CrossRef]
56. Kang, T.H.; Lee, J.H.; Song, C.K.; Han, H.D.; Shin, B.C.; Pai, S.I.; Hung, C.F.; Trimble, C.; Lim, J.S.; Kim, T.W.; et al. Epigallocatechin-3-gallate enhances CD8+ T cell-mediated antitumor immunity induced by DNA vaccination. Cancer Res. 2007, 67, 802–811. [CrossRef] [PubMed]
57. Li, T.; Fan, G.X.; Wang, W.; Li, T.; Yuan, Y.K. Resveratrol induces apoptosis, influences IL-6 and exerts immunomodulatory effect on mouse lymphocytic leukemia both in vitro and in vivo. Int. Immunopharmacol. 2007, 7, 1221–1231. [CrossRef] [PubMed]
58. Akbarzadeh, A.; Rezaei-Sadabady, R.; Davaran, S.; Joo, S.W.; Zarghami, N.; Hanifehpour, Y.; Samiei, M.; Kouhi, M.; Nejati-Koshki, K. Liposome: Classification, preparation, and applications. Nanoscale Res. Lett. 2013, 8, 102. [CrossRef] [PubMed]
59. Narayanan, N.K.; Nargi, D.; Randolph, C.; Narayanan, B.A. Liposome encapsulation of curcumin and resveratrol in combination reduces prostate cancer incidence in pten knockout mice. Int. J. Cancer 2009, 125, 1–8. [CrossRef] [PubMed]
60. Manikandan, R.; Beulaja, M.; Arulvasu, C.; Sellamuthu, S.; Dinesh, D.; Prabhu, D.; Babu, G.; Vaseeharan, B.; Prabhu, N.M. Synergistic anticancer activity of curcumin and catechin: An in vitro study using human cancer cell lines. Microscopy Res. Tech. 2012, 75, 112–116. [CrossRef] [PubMed]
61. Majumdar, A.P.; Banerjee, S.; Nautiyal, J.; Patel, B.B.; Patel, V.; Du, J.; Yu, Y.; Elliott, A.A.; Levi, E.; Sarkar, F.H. Curcumin synergizes with resveratrol to inhibit colon cancer. Nutr. Cancer 2009, 61, 544–553. [CrossRef] [PubMed]
62. Lund, K.C.; Pantuso, T. Combination effects of quercetin, resveratrol and curcumin on in vitro intestinal absorption. J. Restor. Med. 2014, 3, 112–120. [CrossRef]
63. Chen, M.H. Cardiac dysfunction induced by novel targeted anticancer therapy: An emerging issue. Curr. Cardiol. Rep. 2009, 11, 167–174. [CrossRef] [PubMed]
64. Wrensch, M.; Bondy, M.L.; Wiencke, J.; Yost, M. Environmental risk factors for primary malignant brain tumors: A review. J. Neuro-Oncol. 1993, 17, 47–64. [CrossRef]
65. Davis, F.G.; Malinski, N.; Haenszel, W.; Chang, J.; Flannery, J.; Gershman, S.; Dibble, R.; Bigner, D.D. Primary brain tumor incidence rates in four united states regions, 1985–1989: A pilot study. Neuroepidemiology 1996, 15, 103–112. [CrossRef] [PubMed]
66. Thomas, A.A.; Ernstoff, M.S.; Fadul, C.E. Immunotherapy for the treatment of glioblastoma. Cancer J. (Sudbury, Mass.) 2012, 18, 59–68. [CrossRef] [PubMed]